These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14132409)

  • 1. CURRENT VIEWS ON THE ETIOLOGY AND TREATMENT OF HYPERTENSION.
    MENDLOWITZ M; BALDWIN DS; KRAMER ML; GOLFINOS A; LARAGH JH; KWIT NT
    J Am Geriatr Soc; 1964 Mar; 12():239-44. PubMed ID: 14132409
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of hypertension of renal origin.
    Hunt JC; Strong CG; Harrison EG; Furlow WL; Leary FJ
    Am J Cardiol; 1970 Sep; 26(3):280-8. PubMed ID: 5505454
    [No Abstract]   [Full Text] [Related]  

  • 3. [RENAL CLEARANCE OF FREE ALDOSTERONE BEFORE AND AFTER APPLICATION OF AN ALDOSTERONE ANTAGONIST].
    GFELLER J
    Z Gesamte Exp Med; 1964 Oct; 138():353-65. PubMed ID: 14316605
    [No Abstract]   [Full Text] [Related]  

  • 4. ANTIHYPERTENSIVE AND PRESSOR AGENTS OF RENAL ORIGIN.
    GROLLMAN A
    Can Med Assoc J; 1964 Jan; 90(4):299-302. PubMed ID: 14111740
    [No Abstract]   [Full Text] [Related]  

  • 5. [Contribution to the treatment of essential hypertension.(Control of blood pressure, active blood volume, venous pressure, circulation time and mineral metabolism after Repicin and spirolactone medication)].
    SCHAEFER HE; WOELFER HJ; SCHNEIDER KW
    Munch Med Wochenschr; 1962 Feb; 104():234-9. PubMed ID: 14497940
    [No Abstract]   [Full Text] [Related]  

  • 6. HYPERTENSION DUE TO RENAL ARTERY OCCLUSION SIMULATING PRIMARY ALDOSTERONISM.
    LAIDLAW JC; YENDT ER; BIRD CE; GORNALL AG
    Can Med Assoc J; 1964 Jan; 90(4):321-5. PubMed ID: 14111744
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
    Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats.
    Pechanova O; Matuskova J; Capikova D; Jendekova L; Paulis L; Simko F
    Kidney Int; 2006 Jul; 70(1):170-6. PubMed ID: 16710350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of spirolactones on manifestations of experimental renal hypertension].
    KLEPPING J; CABANNE F; BRIET S; MICHIELS R
    J Med Lyon; 1962 Feb; 43():213-26. PubMed ID: 14456894
    [No Abstract]   [Full Text] [Related]  

  • 10. HYPERTENSION AND RENAL DISEASE.
    DUFFIE ER; HOLLIDAY MA
    Pediatr Clin North Am; 1964 Aug; 11():723-30. PubMed ID: 14328546
    [No Abstract]   [Full Text] [Related]  

  • 11. EFFECT OF AN ALDOSTERONE ANTAGONIST ON ELECTROLYTES AND JUXTAGLOMERULAR GRANULARITY IN ADRENAL REGENERATION HYPERTENSION.
    RAPP JP
    Endocrinology; 1964 Sep; 75():326-32. PubMed ID: 14235399
    [No Abstract]   [Full Text] [Related]  

  • 12. Spironolactone in hypertensive patients. Oligemic and antihypertensive effects.
    GEORGOPOULOS AJ; DUSTAN H; PAGE IH
    Arch Intern Med; 1961 Sep; 108():389-92. PubMed ID: 13704490
    [No Abstract]   [Full Text] [Related]  

  • 13. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METHYLDOPA IN TREATMENT OF HYPERTENSION DUE TO CHRONIC RENAL DISEASE.
    LUKE RG; KENNEDY AC
    Br Med J; 1964 Jan; 1(5374):27-30. PubMed ID: 14071629
    [No Abstract]   [Full Text] [Related]  

  • 15. [MODIFICATIONS OF RENAL HEMODYNAMICS IN HYPERTENSION IN RELATION TO AGE, TO THE TYPE OF HYPERTENSION AND TO ANTIHYPERTENSIVE TREATMENT].
    DENICOLA P; GIRALDI A; MAINIERI L; CHERIELIGNIERE EL
    G Gerontol; 1964 Mar; 12():450-75. PubMed ID: 14164378
    [No Abstract]   [Full Text] [Related]  

  • 16. Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
    Lincevicius GS; Shimoura CG; Nishi EE; Perry JC; Casarini DE; Gomes GN; Bergamaschi CT; Campos RR
    Am J Hypertens; 2015 Sep; 28(9):1083-90. PubMed ID: 25628418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [RENAL HYPERTENSION].
    UEDA H; TAKEDA T; IKEDA T; ISHII A
    Naika; 1963 Dec; 12():1049-59. PubMed ID: 14100320
    [No Abstract]   [Full Text] [Related]  

  • 18. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone receptor antagonists for hypertension: what do they offer?
    Liew D; Krum H
    Drugs; 2003; 63(19):1963-72. PubMed ID: 12962513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of aldosterone blockade in resistant hypertension.
    Egan BM; Li J
    Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.